Happy Tuesday, Hospitalogists,

Got an interesting one for you. I had Dorothy Kilroy, the Chief Commercial Officer at Oura, on the podcast recently, and this conversation surprised me. I went in expecting a consumer wearables story and came out thinking Oura might be quietly building one of the more compelling engagement platforms in healthcare.

6x engagement vs. prior programs in Medicare Advantage.

77% of members active 5+ days a week.

A custom women's health LLM built by in-house clinicians.

A hypertension study headed for FDA submission.

And a Cigna partnership that's less about wellness perks and more about redesigning chronic care around continuous biometric data.

We also got into imposter syndrome, the juggle of executive parenthood, and why awareness beats perfection.

Enjoy!

Was this email forwarded to you?

Subscribe Here

BLAKE'S BREAKDOWN

Oura's Healthcare Pivot: How a Smart Ring Is Outperforming Every Engagement Play in Digital Health by 6x

Look, I'll be the first to admit that booking the CCO of a consumer wearables company on Claims Denied felt like a stretch. Oura makes rings. I write about health system M&A and payer dynamics and whether your favorite nonprofit system is actually, you know, profitable. But Dorothy Kilroy walked me through what Oura is doing on the enterprise side, and by the end of the conversation I was sitting there thinking: this company might have accidentally solved the one problem that has defeated basically every digital health engagement play I've ever covered.

People actually use the product.

That's it. That's the moat. And if you've spent any time watching digital health companies burn through $50M in venture capital only to post 12% utilization rates at month three, you understand why that statement carries more weight than it sounds like it should.

The Engagement Numbers Are Absurd

Dorothy shared the data from Oura's partnership with Essence Healthcare (part of the Lumeris network, MA plan), and I genuinely did a double take.

They're seeing 6x the engagement Essence had from prior programs. Members are hitting the Oura app 3-4x per day. 77% are active 5+ days a week. And average daily ring wear time is 23.8 hours. Twenty-three point eight. These people are essentially never taking the ring off.

For context, the entire digital health graveyard is full of companies that had wonderful clinical evidence and catastrophic utilization. The RPM sector alone has been promising connected care transformation for years, and the dirty secret is that most programs struggle to keep patients engaged past the initial onboarding honeymoon. Oura is posting compliance metrics that would make any population health team weep.

The difference, and Dorothy was sharp about this, is that Oura started as a consumer product people genuinely wanted. Sleep tracking was the entry point (universal, non-threatening, immediately actionable), and the healthcare use cases got layered on top of an already sticky user experience. It's a pull model. Most digital health is push. That distinction matters enormously when you're trying to get a 72-year-old MA member to engage with their health between PCP visits.

Dorothy called the concept "connected member care," which I thought was the right framing. When you move from sleep alone to heart health, stress, resilience, recovery, and metabolic signals, you get a longitudinal picture that care teams can actually use. And because the data is personalized (Dor versus Dor, not Dor versus a population average), it starts to look like the personalized health intelligence layer that everyone in healthcare has been talking about for 15 years but nobody has actually built at scale.

Women's Health as the Strategic Wedge Nobody Saw Coming

I was not expecting women's health to be this central to the Oura thesis, but it makes a ton of sense once you hear the science.

The ring sits on the finger. That matters because the finger gives you a signal that's roughly 100x better than the wrist (bone, hair, and poor vasculature make wrist-based readings noisy). And the ring monitors temperature continuously, which turns out to be exquisitely sensitive to hormonal fluctuations. So Oura can predict menstrual cycle timing, identify ovulation windows, track pregnancy by gestational age, and now surface perimenopause patterns, all from a ring you charge once a week.

Dorothy dropped a line that stuck with me: "We are not small men, and our physiology is really unique." Obvious statement, sure. But the reality is that most health data models have been built on male-normative baselines, and women have been shoehorned into those frameworks for decades. Oura is building AI models trained exclusively on women's physiology, and they've gone a step further by developing a custom women's health LLM vetted by in-house clinicians.

Here's what I thought was the smartest design decision: the LLM is intentionally tuned to be non-dismissive, reassuring, and emotionally supportive. If you've ever talked to a woman about her experience in a traditional clinical setting (or if you are one), you know that dismissiveness is one of the most persistent complaints. Oura baked the fix directly into the AI layer. That's not a chatbot. That's a product philosophy.

The fertility use case alone is enormous. My wife and her friends are all over this stuff. But layer in the hypertension-during-pregnancy angle that Dorothy hinted at and you start to see why the clinical validation path could unlock massive payer subsidization.

The March from Wellness Perk to Clinical Risk Signal

This is the part Hospitalogy readers should pay closest attention to, because the strategic trajectory here is significant.

Oura is deliberately moving from "nice wellness benefit" to "clinically validated tool that generates risk signals and changes care pathways." They have an IRB-approved hypertension study launching through Oura Labs with the explicit goal of FDA submission. They have a live Dexcom CGM integration. They're collecting longitudinal data on members taking GLP-1s (the metabolic health angle here is obvious and timely). And they have 40 PhDs and MDs on staff, led by CMO Dr. Ricky Bloomfield.

That's not a consumer hardware company dabbling in health. That's a deliberate clinical infrastructure buildout.

Why does this matter? Because the economics shift entirely once you cross the line from wellness to clinical. Payers and employers will fully subsidize a device that demonstrably reduces utilization, catches hypertension earlier, or improves chronic care outcomes. Oura already has the engagement data to make the ROI argument. The missing piece is FDA-cleared clinical features, and they're actively working on closing that gap.

Dorothy was direct about the ambition: "We don't just want to play on the surface. We want to really change health outcomes." I believed her, mostly because the investment profile (40 PhDs, IRB studies, FDA pipeline) is consistent with the words.

The Cigna Partnership Tells You Where Payers Are Headed

Oura's Cigna deal is worth reading as a signal, not just a press release. Cigna is offering Oura through employer wellness programs where employers can cover the ring cost. Hundreds of day-one signups, strong initial interest, the usual metrics you'd expect from a shiny new benefit.

But the strategic intent underneath is more interesting. Dorothy described Cigna as wanting to "redesign chronic care and member engagement around continuous, worn, high-quality biometric data." That's a fundamentally different thesis than traditional RPM, which has largely focused on acute and post-discharge monitoring. Cigna is betting on the prevention layer, the always-on baseline that surfaces deviations before they become ED visits and inpatient admissions.

I pushed Dorothy on how Oura differs from RPM companies, and she was blunt: RPM has focused on acute care, not preventative care. Oura sits upstream. And critically, Oura's members actually wear the thing and engage with the data, which is the part RPM has historically struggled with (to put it charitably).

If Cigna's thesis proves out, and the engagement numbers from Essence suggest it might, expect more large payers to follow. The logic is straightforward: if continuous biometric data from an engaged member base can reduce downstream utilization, the ring pays for itself many times over.

The Behavior Change That Actually Works

My favorite moment in the conversation was the alcohol data. Oura sees about a 20% reduction in alcohol intake among members who discover the impact on their own physiology. Elevated resting heart rate. Tanked HRV. Higher stress scores. Degraded deep sleep and REM.

I've experienced this myself. You see the recovery score crater after a night out and it's genuinely humbling. But Dorothy's broader point is the one that matters for population health: behavior change is the single hardest problem in healthcare. Warnings don't work. Physician counseling barely moves the needle. But when people see their own body's response to a behavior, in their own data, the feedback loop actually drives change.

A 20% reduction in alcohol consumption is a remarkable behavioral metric. If that kind of data-driven behavior change can be replicated across other modifiable risk factors (diet, sleep hygiene, stress management, medication adherence), the population health implications are significant. And Oura has the engagement to sustain the feedback loop, which is the part every other behavior change intervention has struggled with.

Data Interoperability Without the Data Dump

I asked Dorothy about the practical challenge of pushing wearable data into clinical workflows, and her framing was good: "filtered intelligence, not data transfer." Clinicians don't need 23.8 hours of raw biometric data per patient per day added to their inbox. They need actionable insights, trend deviations, and risk signals delivered in the right context at the right time.

She was also emphatic on privacy: no data sharing without explicit consent, no selling of data, full stop. That's table stakes in 2026, but given how many health tech companies have fumbled the data trust question, it's worth noting that Oura appears to take it seriously. If you're going to sit at the intersection of consumer wellness and clinical care, you cannot afford a data privacy scandal. One breach and the engagement moat evaporates overnight.

The Partnership Playbook

Dorothy's partnership criteria were refreshingly practical. They're looking for partners who want to drive outcomes (not just access data), fit into real clinical workflows, meet Oura's privacy standards, and complement Oura's signal with additive data layers (metabolic, clinical, etc.).

But the best criterion was the last one: "People do deals. People do partnerships. Companies don't." She talked about looking across the table at potential partners and evaluating whether the person has the innovative spirit and aligned incentives to actually execute. It's the je ne sais quoi of partnership selection, and honestly, it's the part that matters most and gets discussed least.

She noted Oura has more partnership opportunities than they have capacity to execute (they're hiring, for those keeping score), and the forward focus areas are: payers and providers driving clinical outcomes, metabolic and cardiovascular health (the GLP-1 longitudinal data play is particularly timely), and clinical AI integrations.

Revenue and Scale

Dorothy owns the commercial number, and she was candid about it: "Revenue solves a lot of problems." Oura has doubled revenue every year for three years and sold over 5.5M rings globally. The growth focus is shifting toward international markets (historically US-heavy) and deeper clinical validation in the US.

One detail I thought was telling: Oura became the first HSA/FSA-eligible wearable, and the majority of members request a receipt for reimbursement. That tells you something about the consumer base. These aren't people casually trying a wellness gadget. They're treating it as a health investment and using tax-advantaged dollars to pay for it.

The access play is core to Dorothy's philosophy. As clinical value increases and payer/employer partnerships deepen, the cost barrier drops for more people. It's a virtuous cycle: better clinical evidence → more payer subsidization → broader access → more data → better algorithms → more clinical evidence. If they can keep the flywheel spinning, the TAM expands well beyond the early-adopter wellness crowd.

So What?

Oura isn't a traditional Hospitalogy company. But that might be exactly the point. The healthcare industry has spent decades and billions of dollars trying to crack engagement, behavior change, and data-driven prevention. The results, broadly, have been underwhelming. Oura is coming at the problem from the consumer side with a product that people voluntarily wear 23.8 hours a day, engagement metrics that embarrass legacy programs, and a deliberate march toward the clinical validation that would unlock the real enterprise market.

The open question is whether a consumer wearable can truly cross the chasm into clinical indispensability, or whether it plateaus as the best wellness perk on the market. The hypertension FDA play will be the tell. If Oura gets clearance and can demonstrate that continuous ring-based monitoring catches hypertension earlier and reduces downstream costs, the payer subsidization floodgates open. If the FDA path stalls, they're still a phenomenal engagement platform, but the ceiling is lower.

Either way, the engagement moat is real. And in a world where every payer, health system, and employer is trying to figure out how to keep members activated and out of the ED, that moat might be the most valuable asset in digital health right now.

ON YOUR RADAR 

• Breakdown: The cardiology physician workforce crunch is getting harder to ignore. Sg2's latest analysis lays out a structural mismatch: cardiovascular demand keeps climbing — inpatient discharges up ~1% annually, outpatient visits up ~2% — while the CV physician workforce is projected to contract by nearly 3% per year. That math doesn't work. The piece goes deeper than the physician supply problem, though. It surfaces the hidden bottlenecks — echo sonographers, cardiac anesthesiologists — that will cap growth even if you manage to recruit. Nearly half of all US counties have no practicing cardiologist. Average cardiology appointment wait times hit 32.7 days in 2025, up 23% since 2022. The pipeline isn't keeping pace. Worth the read if you're thinking about CV program strategy, capital allocation, or workforce planning over the next 3-5 years.

• Read: CMS released updated hospital star ratings on May 13, with 94 more hospitals earning a five-star quality rating in 2026 compared to 2025. Meanwhile, 199 hospitals were assigned one star for overall quality. Read more.

• Roundtable: This month’s Roundtable, usually just for Plus members, is going to be a little different. We’re opening it up to all Hospitalogy Members! Join us Friday, May 22 at 1PM EDT. Register here.

That’s all for this Tuesday. I would love to know your thoughts! Just hit reply to this email.

– Blake